摘要
表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)能显著改善EGFR激活突变的晚期非小细胞肺癌(NSCLC)患者的生存期。几乎所有EGFR突变的NSCLC肿瘤最终都获得了对EGFRTKIs的耐药性,而获得EGFR-TKIs耐药性是目前治疗EGFR突变的NSCLC面临的巨大挑战。近几年来,在EGFR-TKI药物的研究及NSCLC的治疗方面有了新的突破,该文就EGFR-TKI与NSCLC的相关临床研究及应用取得的进展进行阐述。
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can significantly improve the survival rate of patients who suffered terminal non-small cell lung cancer (NSCLC) with EGFR activating mutations. Almost all NSCLS with EGFR mutations eventually acquire resistance to EGFR-TKIs, which is a huge challenge on effective treatments. In recent years, there have been new breakthroughs in the research of EGFR-TKI and the treatment of NSCLC. This article describes the recent progresses in the clinical research and application of EGFR-TKI and NSCLC.
作者
续文栋
吕朋
李健
王昊
马金山
Xu Wendong 1, Lyu Peng 1, Li Jian 1, Wang Hao 1, Ma Jinshan 2.(1.Department of Thoracic Surgery,Tianjin Medical University General Hospital Airport Hospital, Tianjin 300300, China; 2.Department of Thoracic Surgery, Xinjiang Uygur Autonomous Region Chest Hospital, Urumchi 830049, China)
出处
《中华胸部外科电子杂志》
2018年第3期184-188,共5页
CHINESE JOURNAL OF THORACIC SURGERY:Electronic Edition
基金
新疆维吾尔自治区自然科学基金(2015211C193)
关键词
表皮生长因子受体
酪氨酸激酶抑制剂
非小细胞肺癌
基因突变
耐药
Epidermal growth factor receptor
Tyrosine kinase inhibitor
Non-small cell lung cancer
Gene mutation
Drug resistance